Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Men with MBC have a similar prognosis compared with women

Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD

Key clinical point: Men with metastatic breast cancer (MBC) have a similar prognosis, compared with women, but gonadal suppression remains a topic of debate.

Major finding: Median PFS was 9.8 months in men, compared with 13.0 months in matched women.

Study details: The ESME study was a large-scale retrospective analysis of 16,701 patients, 149 of whom were men with MBC. Male-GBG54 was a prospective, randomized trial involving 46 MBC patients who received three different endocrine therapies.

Disclosures: Discussant Dr. Schroeder disclosed financial relationships with Novartis, Roche, Genentech, and others. Male-GBG54 was funded by Claudia von Schilling Foundation.

Read the article here.

Citation:

Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD.

This Week's Must Reads

Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

Must Reads in Breast Cancer

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292

Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD

Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.